Inferra AIResearch Tools

Inferra AI / Company / RLAY

Relay Therapeutics, Inc.

RLAY · Health Care

Last earnings Aug 6, 2026

Key results

Revenuequarter

$0.7 million

Revenue: Revenue was $0.7 million for the second quarter of 2025, as compared to $0 for the second quarter of 2024.

SEC original ↗Relay Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025

AI analysis

Q2 2025 · reported Aug 7, 2025

Based on: Earnings release + parent 8-K — transcript not held

Revenue · Q2 2025
$0.7M
EX-99 · Aug 7, 2025

Headline figures

MetricQ2 2025Prior qtrYear ago
Revenue$0.7 million——

EX-99 · Aug 7, 2025

Guidance · company-stated

No guidance located in the held release

Next earningsNo verified date on fileNo date is estimated or imported

Capital allocation

The company expects its current cash, cash equivalents, and investments will be sufficient to fund its operating expenses and capital expenditure requirements into 2029.

General educational research only — not investment advice.Every figure is as stated in the held documents; values marked “computed from stated figures” are arithmetic on those stated figures. Guidance shown is the company’s own stated guidance. No price targets, no recommendations, no consensus estimates.

Event summary

Relay Therapeutics, Inc. Q2 2025 — Revenue: Revenue was $0.7 million for the second quarter of 2025, as compared to $0 for the second quarter of 2024.

Based on: Earnings release + parent 8-K — transcript not held

Guidance & outlook

No guidance located in the held release

Capital allocation

The company expects its current cash, cash equivalents, and investments will be sufficient to fund its operating expenses and capital expenditure requirements into 2029.

SEC original ↗Relay Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025

Strategy & priorities

It is our company’s top priority to enroll patients and execute this trial, and hopefully deliver a novel medicine in the post-CDK4/6 breast cancer setting where there is a large unmet medical need.

SEC original ↗Relay Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025

The decrease of $28.1 million was primarily due to the series of strategic choices made to streamline the research organization throughout 2024 and 2025, as well as cost avoidance on continued development of lirafugratinib after execution of the license agreement with Elevar Therapeutics, Inc.

SEC original ↗Relay Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025

Risks & headwinds

These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Relay Therapeutics’ most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, as well as any subsequent filings with the Securities and Exchange Commission.

SEC original ↗Relay Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025

Competitors

Competitors & peers

Same GICS sector — classification peers, not declared competitors

Gilead Sciences (GILD) Health CareGenmab (GMAB) Health CareAlcon (ALC) Health CareArgenx (ARGX) Health CareSanofi (SNY) Health CareMerck & Co. (MRK) Health CareXencor Inc (XNCR) Health CareIllumina, Inc. (ILMN) Health Care
Documents

Filings

33 documents

Earnings releases

12 documents

Presentations

0 documents

No presentations for Relay Therapeutics, Inc. are held in this edition of the library.

Transcripts

0 documents

No transcripts for Relay Therapeutics, Inc. are held in this edition of the library.

See also the earnings calendar for every tracked company’s next earnings date.